| Name | zapnometinib |
| Description | Zapnometinib (ATR-002) is a MEK inhibitor. |
| In vitro | Zapnometinib inhibits MEK, with IC50s of 30.96 nM, 357 nM, and 15 nM in cell free kinase assay, A549, MDCK cells and human PBMCs[1].Zapnometinib reduces the viral titers of the IV H1N1pdm09, H3N2[1]. |
| In vivo | Zapnometinib exhibits AUC values of 860.02 and 1953.68 μg?h/mL in mice by i.v. or oral route, respectively[1].Zapnometinib reduces the lung virus titers and enhances survival of mice after lethal H1N1pdm09 infection[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.88 mM), Sonication is recommended. DMSO : 60 mg/mL (146.5 mM), Sonication is recommended.
|
| Keywords | zapnometinib | virus | PD-0184264 | PD 0184264 | Mitogen-activated protein kinase kinase | MEK | MAPKK | MAP2K | Inhibitor | inhibit | InfluenzaVirus | Influenza Virus | influenza | CI-1040 | Bacterial | ATR002 | ATR 002 | antiviral | antibacterial |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | ReFRAME Related Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Fibrosis Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |